Kyntra Bio Inc

Research Kyntra Bio Inc (KYNB) on Bullrun: market cap USD 29.59M, P/E 0.3. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerKYNB
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 29.59M
• P/E0.3
• Financial periodFY2025
• RevenueUSD 6.44M
• Revenue growth-78.3%
• Net incomeUSD 183.45M
• Free cash flow-USD 4.81M
• Gross margin91.4%

Valuation Snapshot

latest market cap is USD 29.59M; P/E is 0.3.

About Kyntra Bio Inc

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers.

Frequently asked questions

What is Kyntra Bio Inc's market cap?

Kyntra Bio Inc's market capitalization is USD 29.59M.

What is Kyntra Bio Inc's P/E ratio?

Kyntra Bio Inc's price-to-earnings (P/E) ratio is 0.3.

What does Kyntra Bio Inc do?

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs.